Controlled study of hepatitis B virus level alteration in hepatocellular carcinoma while treating with transcatheter arterial chemoembolisation alone or in combination with interferon-alpha

ISRCTN ISRCTN85736336
DOI https://doi.org/10.1186/ISRCTN85736336
Secondary identifying numbers N/A
Submission date
10/01/2009
Registration date
15/05/2009
Last edited
15/05/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Maoquan Li
Scientific

Interventional Department
Affiliated 10th People's Hospital of Tongji University
No. 301 Middle Yanchang Road
Shanghai
200072
China

Email cjr.limaoquan@vip.163.com

Study information

Study designRandomised controlled non-blinded single-centre study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleControlled study of hepatitis B virus level alteration in hepatocellular carcinoma: monotherapy with transcatheter arterial chemoembolisation versus double therapy with transcatheter arterial chemoembolisation and interferon-alpha: a randomised controlled trial
Study objectivesHepatitis B virus (HBV) has been proved as one principal inducer of hepatiocellular carcinoma (HCC) by epidemiology study and animal experiment. And for many unresectable HCC, transcatheter arterial chemoembolism (TACE) is the most effective way to relieve the disease and elongate life. However, some studies have revealed that TACE may reactivate HBV replication and result in worse prognosis in HCC patients.

Some evidences show that interferon-alpha (IFN-a) can reduce HBV level effectively and safely. In addition, IFN-a has also been proved a worthful therapy to HBV-related HCC with postponed recurrence and prolonged life time. We assume that at the same time of TACE treatment, administration of IFN-a may suppress the reactivation of HBV replication. To test our assumption, we designed a randomised controlled study in HCC patients with positive hepatitis B surface antigen (HBS-Ag) and hepatitis B e antigen (HBe-Ag) to evaluate the efficacy of HBV inhibition and survival by double therapy with TACE and IFN-a versus monotherapy with TACE.
Ethics approval(s)Ethics Committee of the Affiliated 10th People's Hospital, Tongji University, approved in October 2008 (ref: 08-10-5).
Health condition(s) or problem(s) studiedHepatitis B virus related hepatocellular carcinoma
InterventionAll included patients will be divided into two groups by randomisation. One group will receive double therapy with TACE and IFN-a, while the other group will receive monotherapy with TACE as control.

A 0.2% emulsion of epirubicin mixed with lipiodine (GUERBET™) is used for TACE in both groups. IFN-a is administered at a dosage of 60 ug every other day for a duration of 6 months. The frequency and total duration of TACE therapy for each group is once per month and 3 times in total. Follow-up for HBV-DNA level, survival and progress free survival (PFS) will last for 6 months.
Intervention typeOther
Primary outcome measure1. HBV reactivation, defined as a greater than 10-fold increase in serum HBV-DNA compared with the baseline level
2. Hepatitis due to HBV reactivation, defined as a threefold or greater increase in serum ALT to a level that exceeded 100 IU/L (reference range less than 33 IU/L) in patients with HBV reactivation in the absence of clinical features of tumour progression, hepatotoxic drugs, treatment-related hepatic damage, or other systemic infections
3. Disease progress, according to the Response Evaluation Criteria in Solid Tumors (RECIST) standard
4. Patient death

The outcomes above will be measured every month after the end of therapy until 6 months.
Secondary outcome measuresSevere complications: unendurable fever, hepatic decompensation, measured every month after the end of therapy until 6 months.
Overall study start date01/12/2008
Completion date01/09/2009

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants116
Key inclusion criteria1. Image or pathologically diagnosed HCC
2. Newly diagnosed HCC
3. Unresectable HCC
4. Positive serum HBS-Ag and HBe-Ag
5. Child-Pugh scale A and B
6. Older than 20 years, either sex
7. Patients without jaundice
Key exclusion criteria1. Previous history of antiviral therapy
2. Baseline serum alanine aminotransferase (ALT) level 2.5 times the upper limit of normal or higher
3. Serum HBV DNA level greater than 107 copies/mL
4. Main portal vein thrombosis
5. Underlying cardiac or renal diseases
6. Positive tests for antibody to hepatitis C virus or human immunodeficiency virus
7. Child–Pugh classification C
8. Pre-existing evidence of hepatic decompensation
Date of first enrolment01/12/2008
Date of final enrolment01/09/2009

Locations

Countries of recruitment

  • China

Study participating centre

Interventional Department
Shanghai
200072
China

Sponsor information

Affiliated 10th People's Hospital of Tongji University (China)
Hospital/treatment centre

No. 301 Middle Yanchang Road
Shanghai
200072
China

Website http://www.shdsyy.com.cn
ROR logo "ROR" https://ror.org/03vjkf643

Funders

Funder type

Hospital/treatment centre

Affiliated 10th People's Hospital of Tongji University (China)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan